81435-67-8|Losulazine HCl|InChI=1S/C27H22F4N4O3S.ClH/c28-20-4-8-22(9-5-20)39(37,38)35-15-13-34(14-16-35)26(36)18-1-6-21(7-2-18)33-24-11-12-32-25-17-19(27(29,30)31)3-10-23(24)25;/h1-12,17H,13-16H2,(H,32,33);1H|-范德生物科技公司

Losulazine HCl

NMR下载 COA and HPLC MSDS下载
names：
InChI=1S/C27H22F4N4O3S.ClH/c28-20-4-8-22(9-5-20)39(37,38)35-15-13-34(14-16-35)26(36)18-1-6-21(7-2-18)33-24-11-12-32-25-17-19(27(29,30)31)3-10-23(24)25;/h1-12,17H,13-16H2,(H,32,33);1H
CAS号：
81435-67-8
MDL Number：
MF(分子式)： C27H23ClF4N4O3S MW(分子量)： 595
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Losulazine HCl
英文别名	Losulazine hydrochloride; Losulazine HCl; Losulazine monohydrochloride;
CAS号	81435-67-8
SMILES	O=C(N1CCN(S(=O)(C2=CC=C(F)C=C2)=O)CC1)C3=CC=C(NC4=CC=NC5=CC(C(F)(F)F)=CC=C45)C=C3.[H]Cl
Inchi	(4-((4-fluorophenyl)sulfonyl)piperazin-1-yl)(4-((7-(trifluoromethyl)quinolin-4-yl)amino)phenyl)methanone hydrochloride
InchiKey
分子式 Formula	C27H23ClF4N4O3S
分子量 Molecular Weight	595
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Losulazine HCl(CAS:81435-67-8):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Losulazine HCl is a new antihypertensive agent.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Pals DT, DeGraaf GL. Cardiovascular effects of losulazine hydrochloride, a peripheral norepinephrine-depleting agent, in nonhuman primates. J Pharmacol Exp Ther. 1985 Feb;232(2):407-12. PubMed PMID: 3968642.

[2]Gore R, Musselman D, Micalizzi E, Slomka M. Losulazine, a new antihypertensive. Clin Pharmacol Ther. 1985 Aug;38(2):195-8. PubMed PMID: 4017421.

[3] Pals DT. Hormonal and cardiovascular effects of losulazine hydrochloride in relation to sodium balance in nonhuman primates. Clin Exp Hypertens A. 1986;8(7):1179-88. PubMed PMID: 3533328.

[4] Pan JT, Hooth MJ, Lookingland KJ, Moore KE, Marks TA. Comparison of the effects of losulazine and reserpine on central aminergic neurons. Toxicol Appl Pharmacol. 1993 Nov;123(1):26-33. PubMed PMID: 8236258.

[5] Mesfin GM, Factor SS, Higgins MJ. Pathologic changes in the accessory sex glands of rats treated with a sympatholytic hypotensive agent (losulazine). Toxicol Pathol. 1989;17(3):516-24. PubMed PMID: 2814227.

6: Mesfin GM, Johnson GA, Higgins MJ, Morris DF. Mechanism of anestrus in rats treated with an antihypertensive agent, losulazine hydrochloride. Toxicol Appl Pharmacol. 1987 Jan;87(1):91-101. PubMed PMID: 3099429.7: Morris DF, Marks TA, Mesfin GM. Effects of losulazine on rat reproduction and development. Fundam Appl Toxicol. 1987 Oct;9(3):573-87. PubMed PMID: 3692015.8: Poppe SM, Marks TA, Mesfin GM, Soule DL, Shaw CI, Morris DF, Black DL. Reproductive and developmental effects on rats after prenatal, postnatal, or pre- and postnatal exposure to the hypotensive agent losulazine. Teratology. 1987 Oct;36(2):171-80. PubMed PMID: 3424203.9: McCall JM, TenBrink RE, Kamdar BV, Skaletzky LL, Perricone SC, Piper RC, Delehanty PJ. 7-(Trifluoromethyl)-4-aminoquinoline hypotensives: novel peripheral sympatholytics. J Med Chem. 1986 Jan;29(1):133-7. PubMed PMID: 3941407.10: Ray A, Chatterjee S, Biswas NM. Study on the activities of testes and accessory sex glands after losulazine treatment in rats. Toxicol Lett. 1994 Sep;73(3):175-83. PubMed PMID: 8091426.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开